Northwest Biotherapeutics, Inc.
NWBO
$0.26
-$0.0096-3.56%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -20.71% | -33.83% | 9.60% | 14.57% | 30.76% |
| Total Depreciation and Amortization | 10.95% | 17.95% | 15.94% | 22.37% | 5.40% |
| Total Amortization of Deferred Charges | -6.76% | 4.38% | -25.58% | -14.78% | -4.69% |
| Total Other Non-Cash Items | 15.71% | 43.10% | -60.11% | -63.80% | -70.76% |
| Change in Net Operating Assets | 3,719.89% | 370.72% | -38.83% | -117.56% | -105.53% |
| Cash from Operations | 1.41% | -6.30% | -18.16% | -24.63% | -7.36% |
| Capital Expenditure | 62.95% | 70.50% | 73.86% | 67.82% | 43.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 62.95% | 70.50% | 73.86% | 67.82% | 43.91% |
| Total Debt Issued | 12.71% | 2.61% | 28.88% | 109.98% | 73.32% |
| Total Debt Repaid | -618.31% | -272.21% | -296.76% | -4.67% | 82.08% |
| Issuance of Common Stock | 604.35% | 817.41% | 328.67% | 45.71% | -79.40% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -68.58% | -38.48% | -34.15% | -29.68% | -30.97% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -98.95% | -85.24% | -78.70% | 9,400.00% |
| Cash from Financing | 7.98% | 7.63% | 11.20% | 24.36% | 3.22% |
| Foreign Exchange rate Adjustments | -205.29% | 347.61% | -41.17% | 272.35% | -69.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 108.11% | 101.01% | 5.11% | 142.76% | -380.96% |